Social networks
556 1,413 13,977Activities
Technologies
Entity types
Location
70 Av. Tony Garnier, 69007 Lyon, France
Lyon
France
Employees
Scale: 51-200
Estimated: 83
SIREN
808370100Engaged corporates
36Added in Motherbase
5 years, 2 months agoThe leading microbiome company in oncology
MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
Hervé Affagard, CEO & Co-founder
Microbiome, Microbiota, Microbiology, pharma, GvHD, Leukemia, Dysbiosis, Symbiosis, Biotech, oncology, cancer, gut microbiota, allo-HSCT, and Gut microbiome
The leading microbiome company in oncology
MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
Hervé Affagard, CEO & Co-founder
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
WAOUP Business Consulting and Services | WAOUP Business Consulting and Services | Other 12 Jun 2024 | | |
Auvergne-Rhone-Alpes Entreprises - Isère National and local authorities, Business Consulting and Services | Auvergne-Rhone-Alpes Entreprises - Isère National and local authorities, Business Consulting and Services | Other 17 Jun 2024 | | |
Biotechnology Innovation Organization | Other 22 May 2024 | | ||
Ministère de la Santé | Other 11 Apr 2024 | | ||
Direction Générale des Entreprises National and local authorities, Government Administration | Direction Générale des Entreprises National and local authorities, Government Administration | Other 29 Mar 2024 | | |
France Travail Human ressources, Government Administration | France Travail Human ressources, Government Administration | Other 21 Dec 2023 | | |
Gouvernement | Other 29 Mar 2024 | | ||
BNP Paribas Bank, Banking | BNP Paribas Bank, Banking | Other 21 Oct 2023 | | |
CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 29 Jun 2023 | | |
Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Other 26 Jun 2023 | |